20th May 2025 11:14
(Alliance News) - Ixico PLC on Tuesday said its loss narrowed in the first half of its financial year, as revenue growth supported its expectations for continued momentum in the second half.
The London-based medical analytics company said its pretax loss narrowed to GBP889,000 in the six months that ended March 31 from GBP1.5 million a year before.
Revenue grew 20% to GBP3.2 million from GBP2.5 million, "putting the company in a strong position to deliver or exceed guidance", Ixico said. Cost of sales rose by just 6.7% to GBP1.6 million from GBP1.5 million, and total operating expenses were reduced 3.4% during the six-month period to GBP2.8 million from GBP2.9 million.
Loss before interest, tax, depreciation and amortisation was GBP700,000, narrowed from GBP1.3 million a year prior.
The order book stood at GBP13.1 million on March 31, up 3.1% from GBP12.7 million a year before, Ixico said.
"The first half of 2025 indicates that our 'innovate lead scale' strategy has created the foundations for a return to growth driven by the diversification of revenue streams, therapeutic areas and market verticals, together with the scope extension of existing client programs," said Chief Executive Officer Bram Goorden.
"It has been a positive first six months defined by disciplined commercial execution, scientific innovation and truly differentiated technology development. My conviction has been further strengthened that the company is going to make an accelerated impact in the thriving space of neurodegenerative disease research."
Shares in Ixico were up 7.5% at 9.68 pence each in London on Tuesday morning. The stock has risen 36% over the past year.
By Emily Parsons, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Ixico